Vedanta Biosciences: Jeffrey Silber
Vedanta Biosciences has appointed Jeffrey Silber, MD, as Chief Medical Officer.
Dr Silber’s experience in drug development spans multiple therapeutic areas at Merck, AbbVie and EMD Serono. He will now guide the advancement of Vedanta’s clinical programmes.
Dr Silber has overseen multiple regulatory submissions and approvals worldwide over his career to date, and held departmental head responsibilities spanning clinical research, project management, programme leadership, pharmacovigilance, biostatistics, epidemiology and translational medicine. His academic and professional awards include the highest honours awarded by Merck Research Laboratories and by Merck & Co.
Dr Silber earned his BA in biology from Harvard University and his MD from Albert Einstein College of Medicine of Yeshiva University; with additional training in internal medicine at New York University/Bellevue Hospital and in infectious diseases at the University of Pennsylvania.
Vedanta Biosciences is developing oral therapies based on rationally defined consortia of bacteria derived from the human microbiome. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy.
